Market Overview

Benzinga's Top Pre-Market Losers

Related FOLD
Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now
Morning Market Gainers
Related GSK
Idera to Collaborate With GSK to Identify 3rd Generation Antisense Molecules for Treatment of Renal Disease
ISIS Pharma Called A 'Sleeper Awakening' At Piper Jaffray

Amicus Therapeutics (NASDAQ: FOLD) shares dropped 46.97% to $3.06 in pre-market trading. Amicus Therapeutics and GlaxoSmithKline plc (NYSE: GSK) today announced the 6-month primary treatment period results from the first Phase 3 global registration study.

Allscripts Healthcare Solutions (NASDAQ: MDRX) shares fell 16.48% to $8.92 in the pre-market trading. Allscripts appointed Paul Black as its CEO.

Accenture plc (NYSE: ACN) dipped 5.21% to $66.73 in the pre-market session. Accenture projects Q2 revenue of $6.9 billion of $7.15 billion, versus analysts' estimates of $7.14 billion.

Bed Bath & Beyond (NASDAQ: BBBY) dipped 4.86% to $57.35 in the pre-market session. Bed Bath & Beyond issued downbeat fourth-quarter earnings forecast. The company's board also authorized a new $2.5 billion share repurchase program.

Posted-In: Top Pre-Market LosersNews Movers & Shakers Pre-Market Outlook Markets


Related Articles (BBBY + ACN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters